Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Application (Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies)
5.2.2. By Indication ( Infectious Diseases, Metabolic & Genetic Diseases, Cardiovascular & Cerebrovascular Diseases)
5.2.3. By End user (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Application
5.3.2. By Indication
5.3.3. By End user
5.3.4. By Region
6. North America mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application
6.2.2. By Indication
6.2.3. By End user
6.2.4. By Country
6.2.4.1. United States mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
6.2.4.1.1. Market Size & Forecast
6.2.4.1.1.1. By Value
6.2.4.1.2. Market Share & Forecast
6.2.4.1.2.1. By Application
6.2.4.1.2.2. By Indication
6.2.4.1.2.3. By End user
6.2.4.2. Canada mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
6.2.4.2.1. Market Size & Forecast
6.2.4.2.1.1. By Value
6.2.4.2.2. Market Share & Forecast
6.2.4.2.2.1. By Application
6.2.4.2.2.2. By Indication
6.2.4.2.2.3. By End user
6.2.4.3. Mexico mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
6.2.4.3.1. Market Size & Forecast
6.2.4.3.1.1. By Value
6.2.4.3.2. Market Share & Forecast
6.2.4.3.2.1. By Application
6.2.4.3.2.2. By Indication
6.2.4.3.2.3. By End user
7. Europe mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Application
7.2.2. By Indication
7.2.3. By End user
7.2.4. By Country
7.2.4.1. France mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
7.2.4.1.1. Market Size & Forecast
7.2.4.1.1.1. By Value
7.2.4.1.2. Market Share & Forecast
7.2.4.1.2.1. By Application
7.2.4.1.2.2. By Indication
7.2.4.1.2.3. By End user
7.2.4.2. Germany mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
7.2.4.2.1. Market Size & Forecast
7.2.4.2.1.1. By Value
7.2.4.2.2. Market Share & Forecast
7.2.4.2.2.1. By Application
7.2.4.2.2.2. By Indication
7.2.4.2.2.3. By End user
7.2.4.3. United Kingdom mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
7.2.4.3.1. Market Size & Forecast
7.2.4.3.1.1. By Value
7.2.4.3.2. Market Share & Forecast
7.2.4.3.2.1. By Application
7.2.4.3.2.2. By Indication
7.2.4.3.2.3. By End user
7.2.4.4. Italy mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
7.2.4.4.1. Market Size & Forecast
7.2.4.4.1.1. By Value
7.2.4.4.2. Market Share & Forecast
7.2.4.4.2.1. By Application
7.2.4.4.2.2. By Indication
7.2.4.4.2.3. By End user
7.2.4.5. Spain mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
7.2.4.5.1. Market Size & Forecast
7.2.4.5.1.1. By Value
7.2.4.5.2. Market Share & Forecast
7.2.4.5.2.1. By Application
7.2.4.5.2.2. By Indication
7.2.4.5.2.3. By End user
8. Asia Pacific mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Application
8.2.2. By Indication
8.2.3. By End user
8.2.4. By Country
8.2.4.1. China mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
8.2.4.1.1. Market Size & Forecast
8.2.4.1.1.1. By Value
8.2.4.1.2. Market Share & Forecast
8.2.4.1.2.1. By Application
8.2.4.1.2.2. By Indication
8.2.4.1.2.3. By End user
8.2.4.2. India mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
8.2.4.2.1. Market Size & Forecast
8.2.4.2.1.1. By Value
8.2.4.2.2. Market Share & Forecast
8.2.4.2.2.1. By Application
8.2.4.2.2.2. By Indication
8.2.4.2.2.3. By End user
8.2.4.3. South Korea mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
8.2.4.3.1. Market Size & Forecast
8.2.4.3.1.1. By Value
8.2.4.3.2. Market Share & Forecast
8.2.4.3.2.1. By Application
8.2.4.3.2.2. By Indication
8.2.4.3.2.3. By End user
8.2.4.4. Japan mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
8.2.4.4.1. Market Size & Forecast
8.2.4.4.1.1. By Value
8.2.4.4.2. Market Share & Forecast
8.2.4.4.2.1. By Application
8.2.4.4.2.2. By Indication
8.2.4.4.2.3. By End user
8.2.4.5. Australia mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
8.2.4.5.1. Market Size & Forecast
8.2.4.5.1.1. By Value
8.2.4.5.2. Market Share & Forecast
8.2.4.5.2.1. By Application
8.2.4.5.2.2. By Indication
8.2.4.5.2.3. By End user
9. South America mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Application
9.2.2. By Indication
9.2.3. By End user
9.2.4. By Country
9.2.4.1. Brazil mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
9.2.4.1.1. Market Size & Forecast
9.2.4.1.1.1. By Value
9.2.4.1.2. Market Share & Forecast
9.2.4.1.2.1. By Application
9.2.4.1.2.2. By Indication
9.2.4.1.2.3. By End user
9.2.4.2. Argentina mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
9.2.4.2.1. Market Size & Forecast
9.2.4.2.1.1. By Value
9.2.4.2.2. Market Share & Forecast
9.2.4.2.2.1. By Application
9.2.4.2.2.2. By Indication
9.2.4.2.2.3. By End user
9.2.4.3. Colombia mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
9.2.4.3.1. Market Size & Forecast
9.2.4.3.1.1. By Value
9.2.4.3.2. Market Share & Forecast
9.2.4.3.2.1. By Application
9.2.4.3.2.2. By Indication
9.2.4.3.2.3. By End user
10. Middle East & Africa mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By Indication
10.2.3. By End user
10.2.4. By Country
10.2.4.1. South Africa mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
10.2.4.1.1. Market Size & Forecast
10.2.4.1.1.1. By Value
10.2.4.1.2. Market Share & Forecast
10.2.4.1.2.1. By Application
10.2.4.1.2.2. By Indication
10.2.4.1.2.3. By End user
10.2.4.2. Saudi Arabia mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
10.2.4.2.1. Market Size & Forecast
10.2.4.2.1.1. By Value
10.2.4.2.2. Market Share & Forecast
10.2.4.2.2.1. By Application
10.2.4.2.2.2. By Indication
10.2.4.2.2.3. By End user
10.2.4.3. UAE mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
10.2.4.3.1. Market Size & Forecast
10.2.4.3.1.1. By Value
10.2.4.3.2. Market Share & Forecast
10.2.4.3.2.1. By Application
10.2.4.3.2.2. By Indication
10.2.4.3.2.3. By End user
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Technology Launches
13. Competitive Landscape
13.1. Danaher corporation (Aldevron)
13.1.1. Business Overview
13.1.2. Patient Offerings
13.1.3. Recent Developments
13.1.4. Key Personnel
13.1.5. SWOT Analysis
13.2. Recipharm AB
13.3. Biomay AG
13.4. Samsung Biologics
13.5. Lonza Group AG
13.6. Catalent , Inc
13.7. Bio-Indication Inc
13.8. Kaneka Eurogentec S.A
13.9. TriLink BioTechnologies
13.10. BioNTech SE
14. Strategic Recommendations
15. About us & Disclaimer